VC
RVNC

Vivo Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Vivo Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-77,373
Closed -$2.13M – 31
2017
Q3 		$2.13M Hold
77,373
– – 0.43% 25
2017
Q2 		$2.04M Hold
77,373
– – 0.51% 24
2017
Q1 		$1.61M Hold
77,373
– – 0.47% 22
2016
Q4 		$1.6M Hold
77,373
– – 0.53% 21
2016
Q3 		$1.25M Hold
77,373
– – 0.39% 18
2016
Q2 		$1.05M Hold
77,373
– – 0.29% 19
2016
Q1 		$1.89M Buy
+77,373
New +$1.57M 0.47% 20

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vivo Capital's RVNC Position: Q4 2017 in Review

Vivo Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2017, closing a stake of 77,373 shares — an estimated $2.13M sold.

Vivo Capital first reported a position in RVNC in Q1 2016 and held it in 7 quarters. The position peaked at $2.13M in Q3 2017. 115 funds tracked by Wall St. Rank hold RVNC as of Q4 2017.

  • Vivo Capital reported no remaining Revance Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Vivo Capital sold 77,373 Revance Therapeutics, Inc. shares in Q4 2017, an estimated $2.13M.
  • Vivo Capital first reported a position in Revance Therapeutics, Inc. in Q1 2016 and held it in 7 quarters.
  • Vivo Capital's Revance Therapeutics, Inc. position peaked at $2.13M in Q3 2017.
  • 115 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2017.

Based on Vivo Capital's 13F filing for Q4 2017, filed 9 Feb 2018.